COMPASS Pathways, Homeostasis Therapeutics, LLC, expected to drive market
The Chronic Pulmonary Hypertension market growth is driven by factors like increase in the prevalence of Chronic Pulmonary Hypertension, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Chronic Pulmonary Hypertension market report also offers comprehensive insights into the Chronic Pulmonary Hypertension market size, share, Chronic Pulmonary Hypertension epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Chronic Pulmonary Hypertension market size growth forward.
Some of the key highlights from the Chronic Pulmonary Hypertension Market Insights Report:
Several key pharmaceutical companies, including COMPASS Pathways, Homeostasis Therapeutics, LLC, and others, are developing novel products to improve the Chronic Pulmonary Hypertension treatment outlook.
In January 2025, AliveGen USA Inc. (AliveGen), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALG-801 for treating pulmonary arterial hypertension (PAH), a rare and life-threatening condition characterized by high blood pressure in the lung arteries, which can lead to right-sided heart failure.
In December 2024, Nicox announced that its Denali Phase III trial, assessing the efficacy and safety of NCX470 for patients with open-angle glaucoma or ocular hypertension, has completed enrollment in China, and screening has concluded.
In November 2024, MediPrint Ophthalmics revealed the results of its Phase IIb clinical trial for LL-BMT1. The trial utilized a new 3D-printed, drug-eluting contact lens for continuous delivery of bimatoprost and hyaluronic acid, successfully meeting all the Phase IIb endpoints.
The prevalence of chronic pulmonary hypertension is expected to rise due to factors such as aging populations, increasing obesity rates, better survival rates among premature infants, environmental influences, genetic factors, improved diagnostics, and a rise in comorbidities.
In 2023, the US represented the largest share of diagnosed chronic pulmonary hypertension patients in the 7MM, with 42%, followed by Japan, which accounted for around 16% of cases. Among European countries, the UK had the highest number of cases, representing approximately 11% of the total 7MM cases.
In 2023, the chronic pulmonary hypertension market was the largest in the US, with a market size of about USD 15,700 million, a figure expected to grow by 2034.
Despite the high prevalence, with around 42,476 thousand cases in the 7MM in 2023, the market for chronic pulmonary hypertension treatment remains limited, with few therapies specifically targeting the condition. However, emerging therapies could significantly impact the market, potentially driving substantial growth.
As per DelveInsight analysis, the Chronic Pulmonary Hypertension market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Chronic Pulmonary Hypertension Market Landscape
Chronic Pulmonary Hypertension Overview
Chronic pulmonary hypertension is a condition characterized by high blood pressure in the lungs, which places strain on the heart and can lead to severe symptoms like shortness of breath and fatigue. It is classified into five groups: Group 1 includes pulmonary arterial hypertension (PAH), Group 2 is pulmonary hypertension caused by left heart disease, Group 3 is pulmonary hypertension linked to lung diseases and/or hypoxia, Group 4 refers to chronic thromboembolic pulmonary hypertension (CTEPH), and Group 5 encompasses pulmonary hypertension with unknown or multifactorial causes. Early detection and proper treatment are essential to improve outcomes and quality of life. Diagnosing chronic pulmonary hypertension involves a combination of clinical assessment, imaging, and specialized tests. Challenges can arise due to the nonspecific nature of the symptoms and the need to differentiate pulmonary hypertension from other cardiovascular and respiratory conditions. Diagnostic methods include echocardiography to evaluate heart function and estimate pulmonary artery pressure, followed by confirmatory tests like right heart catheterization, which directly measures pulmonary artery pressures. Accurate interpretation of results can be challenging, especially in cases where other heart or lung conditions are present, requiring a thorough differential diagnosis.
Do you know the treatment paradigms for different countries? Download our Chronic Pulmonary Hypertension Market Sample Report
Chronic Pulmonary Hypertension Epidemiology Insights
The number of chronic pulmonary hypertension cases in the US is projected to grow at a significant compound annual growth rate (CAGR) by 2034, starting from approximately 17,910 thousand cases in 2023.
In Europe, Germany had the highest prevalence of chronic pulmonary hypertension, accounting for 26% of cases, followed by the UK in 2023. Conversely, Spain had the lowest prevalence, with around 15% of the total diagnosed cases of chronic pulmonary hypertension in the same year.
Chronic Pulmonary Hypertension Epidemiology Segmentation
DelveInsight's Chronic Pulmonary Hypertension market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Chronic Pulmonary Hypertension historical patient pools and forecasted Chronic Pulmonary Hypertension patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Chronic Pulmonary Hypertension Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
Chronic Pulmonary Hypertension Prevalence
Age-Specific Chronic Pulmonary Hypertension Prevalence
Gender-Specific Chronic Pulmonary Hypertension Prevalence
Diagnosed and Treatable Cases of Chronic Pulmonary Hypertension
Visit for more @ Chronic Pulmonary Hypertension Epidemiological Insights
Chronic Pulmonary Hypertension Market Outlook
Phosphodiesterase-5 (PDE-5) inhibitors like Sildenafil and Tadalafil help reduce vascular smooth muscle cell proliferation and promote vasodilation. Endothelin receptor antagonists, including Ambrisentan, Bosentan, and Macitentan, counteract vasoconstriction and smooth muscle cell growth in the pulmonary arteries. Commonly used calcium channel blockers, such as Nifedipine, diltiazem, and amlodipine, are recommended for treating Pulmonary Arterial Hypertension (PAH). Prostacyclins like epoprostenol, treprostinil, and iloprost improve functional capacity and survival in PAH patients.
Additionally, IP prostacyclin receptor agonists, which activate the prostacyclin pathway, are also used for chronic pulmonary hypertension (PH). Endothelin receptor antagonists reduce endothelin-1 levels, which cause constriction and changes in the pulmonary blood vessels in PAH patients.
PDE-5 inhibitors and soluble guanylate cyclase (sGC) stimulators help lower enzyme levels that produce nitric oxide (NO), a substance that relaxes pulmonary blood vessels. By increasing cyclic GMP levels, these drugs promote vasodilation. PDE-5 inhibitors prevent the breakdown of cyclic GMP, while sGC stimulators enhance cyclic GMP production when NO binds to the sGC enzyme, making them effective treatments for PAH.
Chronic Pulmonary Hypertension Marketed Drugs
ADEMPAS (riociguat): Bayer
Chronic Pulmonary Hypertension Emerging Drugs
CS1: Cereno Scientific AB
Chronic Pulmonary Hypertension Key Companies
COMPASS Pathways, Homeostasis Therapeutics, LLC, and others
For more information, visit Chronic Pulmonary Hypertension Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Chronic Pulmonary Hypertension Market Report:
11 Years Forecast
7MM Coverage
Descriptive overview of Chronic Pulmonary Hypertension, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Chronic Pulmonary Hypertension epidemiology in the 7MM
Chronic Pulmonary Hypertension marketed and emerging therapies
Chronic Pulmonary Hypertension companies
Chronic Pulmonary Hypertension market drivers and barriers
Table of Contents:
1 Chronic Pulmonary Hypertension Market Key Comprehensive Insights
2 Chronic Pulmonary Hypertension Market Report Introduction
3 Competitive Intelligence Analysis for Chronic Pulmonary Hypertension
4 Chronic Pulmonary Hypertension Market Analysis Overview at a Glance
5 Executive Summary of Chronic Pulmonary Hypertension
6 Chronic Pulmonary Hypertension Epidemiology and Market Methodology
7 Chronic Pulmonary Hypertension Epidemiology and Patient Population
8 Chronic Pulmonary Hypertension Patient Journey
9 Chronic Pulmonary Hypertension Treatment Algorithm, Chronic Pulmonary Hypertension Current Treatment, and Medical Practices
10 Key Endpoints in Chronic Pulmonary Hypertension Clinical Trials
11 Chronic Pulmonary Hypertension Marketed Therapies
12 Chronic Pulmonary Hypertension Emerging Therapies
13 Chronic Pulmonary Hypertension: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Chronic Pulmonary Hypertension
16 Chronic Pulmonary Hypertension Market Key Opinion Leaders Reviews
18 Chronic Pulmonary Hypertension Market Drivers
19 Chronic Pulmonary Hypertension Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Chronic Pulmonary Hypertension Epidemiology 2034
DelveInsight's "Chronic Pulmonary Hypertension - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Pulmonary Hypertension epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Chronic Pulmonary Hypertension Pipeline 2024
"Chronic Pulmonary Hypertension Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Pulmonary Hypertension market. A detailed picture of the Chronic Pulmonary Hypertension pipeline landscape is provided, which includes the disease overview and Chronic Pulmonary Hypertension treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Motorcyclist killed after crashing, falling over Downtown overpass
A motorcyclist is dead after crashing and falling at least 20 feet over the side of a downtown Cincinnati overpass, police say. The man, who was wearing a helmet, was pronounced dead at the scene of the crash Tuesday night, according to Cincinnati Police Lt. Patrick Caton. It occurred on Fort Washington Way, near the Heritage Center, around 7:45 p.m. on June 10. Witnesses reported seeing a motorcyclist crash into a barrier on the right side of Fort Washington Way, Caton said. The motorcyclist was ejected over the barrier and down more than 20 feet to the southern entrance to the Lytle Tunnel from Third Street, they told police. Speed is considered a factor, according to the lieutenant. Fort Washington Way to Columbia Parkway was shut down for several hours overnight. It reopened early Wednesday, June 11, police said. The crash remains under investigation. This story may be updated. Enquirer media partner Fox 19 provided this report. This article originally appeared on Cincinnati Enquirer: Motorcyclist dead after crash and fall from overpass
Indian Express
4 minutes ago
- Indian Express
Ranbir Kapoor plays foosball with Aamir Khan's son Azad, guess who won? Watch
Aamir Khan recently hosted his close friends and the star cast of his upcoming film Sitaare Zameen Par at his residence for a special screening. The get-together was made extra special as actor Ranbir Kapoor came as a 'surprise' to meet the film's team and also the actor's family and friends. Ranbir Kapoor, who has been busy shooting for his upcoming film Love & War, took some time off his busy schedule to be a part of this gathering. In the inside clips from the event, Ranbir was seen playing a fun foosball match with Aamir Khan's son, Azad. Ranbir looked really serious at the game he played Aamir Khan's house party. Azad was also seen by Ranbir's side and totally involved in the game. The video Ranbir sporting a casual look in an all-black outfit while Azad too was seen in black. See video of Ranbir Kapoor and Aamir Khan's son Azad's foosball game: A post shared by Instant Bollywood (@instantbollywood) In another clip, shared by Aamir's ex-wife Kiran Rao, Ranbir was seen making a surprise entry at Aamir's house. Ranbir was not just seen meeting and greeting the Sitaare Zameen Par cast, but also gifted his newly launched clothing brand's caps to them. The film Sitaare Zameen Par features a cast of ten neurodivergent actors, including individuals with autism, Down syndrome, and other conditions, who play lead roles. These actors include Aroush Datta, Gopi Krishnan Varma, Samvit Desai, Vedant Sharma, Ayush Bhansali, Ashish Pendse, Rishi Shahani, Rishabh Jain, Naman Mishra, and Simran Mangeshkar. Sharing the clip, Kiran wrote, 'Team Sitaare had a surprise guest at their party a few nights ago – who really made their day, as you can see. ♥️🥰 Thank you Ranbir, for your love and your time – and the fantastic ARKS merch! 🥳.' See Ranbir Kapoor's video from Aamir's house: A post shared by Kiran Rao (@raodyness) The film, Sitaare Zameen Par, is a spiritual sequel to the 2007 film Taare Zameen Par, is scheduled for a theatrical release on June 20. The film features Aamir Khan and Genelia Deshmukh in prominent roles. The film was also in the news recently after author and philanthropist Sudha Murthy reviewed and called it an eye-opener. She shared that the Aamir Khan-starrer is 'a beautiful film' and expressed that Sitaare Zameen Par has the potential to bring a lot of change in society. Kriti works as a Copy Editor for the Entertainment section of Indian Express Online ( She is great at web stories, galleries, and Express Archive's photo stories. She is good at spotting stories from social media posts. She makes the copies well-loaded with content, photos, tweets, and other related social media posts to make it interesting for the readers. An alumnus of Asian College of Journalism, Chennai (Specialization in New Media), Kriti has been a part of the organisation since November 2015. She took a transfer from Delhi to Bengaluru in April 2017. ... Read More
Daily Mail
4 minutes ago
- Daily Mail
NASA issues urgent update on 'city killer' asteroid heading towards the moon in 2032
The 'city killer' asteroid 2024 YR4 may not be on a collision course with Earth anymore. But NASA has raised the odds of it hitting the moon in just seven years' time. According to the space agency, there's now a 4.3 per cent chance that 2024 YR4 will smash into the moon on December 22, 2032. The impact event could be visible from Earth as a bright flash of light, as lunar material is ejected into space. Only discovered at the end of last year, 2024 YR4 is somewhere between 174 and 220 feet (53 and 67 metres) in diameter – around the same size as a Boeing 747. If the space rock were to hit Earth, it would create a blast equivalent to detonating 7.7 megatons of TNT and leave a 3,000-foot-wide crater in the ground. The shockwave radiating out from the impact would wipe out an area the size of a major city, which is why it has been designated a 'city-killer'. Fortunately, the chance of it hitting Earth is effectively nil, but the new NASA observations increase the likelihood of it hitting the moon. The new odds are slightly raised from the previous 3.8 per cent chance of 2024 YR4 colliding with the moon, according to NASA. 'As data comes in, it is normal for the impact probability to evolve,' said Molly Wasser, public affairs officer for NASA's Planetary Defense Coordination Office. At more than 30 million miles away, asteroid 2024 YR4 is now too distant to detect with telescopes on Earth. So NASA has been relying on observations from the James Webb Space Telescope (JWST), which is positioned in space about 1 million miles away from us. Asteroid 2024 YR4 is currently on a wide 'elliptical' (not perfectly circular) orbit around the sun, taking it even further from us before. Further updates will not be possible until 2028 when the space rock comes back around towards Earth and becomes bright enough to be detected again. Bu before it escaped from its view, JWST managed to collect one more observation of the object, made using its near-infrared camera last month. 'With the additional data, experts from NASA's Center for Near-Earth Object Studies at the agency's Jet Propulsion Laboratory in southern California further refined the asteroid's orbit,' said Wasser. Asteroid 2024 YR4 is currently on a wide 'elliptical' (not perfectly circular) orbit around the sun, while is taking it even further from us before it comes back around. This image shows the orbit 2024 YR4 in purple with the sun in the centre and orbits of planets (Mercury = cyan; Venus = yellow; Earth = dark blue; Mars = red). Note the asteroid's position (purple dot) in relation to Earth (dark blue dot) about a month before an impact might happen When it zooms back towards the inner solar system, the asteroid will reach an astonishing 85 million miles per hour (38,000 km per second). Asteroids speed up as they approach the sun because of the increased gravitational pull from the sun as they get closer – a bit like an object travelling faster the closer it gets to the ground on Earth. In the event that the asteroid did hit the moon, it would not alter our natural satellite's orbit around Earth, according to NASA. However, it would create a huge crater, ejecting rocky lunar material into space, and generating a bright flash, which should be visible from Earth. The impact event would be the first time scientists could watch a known asteroid create a lunar crater in real-time. The data gathered from this impact could help scientists understand more about other craters on the lunar surface. It is worth nothing that there is a 95.7 per cent chance that it won't hit the moon at all, as it stands – and the probability will likely continue to rise and fall. Asteroid 2024 YR4 was discovered on December 27, 2024 – and soon became a global matter of concern. 2024 YR4 set alarm bells ringing at the world's space agencies in February when its probability of hitting Earth reached a peak of one-in-32, or 3.1 per cent. Thankfully, about a week later, the odds were vastly downgraded just 0.0039 per cent, or one in 26,000. Asteroid 2024 YR4 is thought to be at least the same size as the Tunguska asteroid – which had an estimated diameter of 130 feet, according to NASA. Tunguska caused the largest impact event in recorded history when it shot through Earth's atmosphere in 1908, flattening 830 square miles (2,150 square km) of forest. Many lost consciousness and at least three people passed away as a direct consequence of the Tunguska event, according to a 2019 study. Experts are concerned that we may detect a civilization-threatening Earth-bound asteroid too late, with not enough time for a mission to knock it off course. DART is one of many concepts of how to negate the threat of an asteroid that have been suggested over the years. Multiple bumps Scientists in California have been firing projectiles at meteorites to simulate the best methods of altering the course of an asteroid so that it wouldn't hit Earth. According to the results so far, an asteroid like Bennu that is rich in carbon could need several small bumps to charge its course. 'These results indicate multiple successive impacts may be required to deflect rather than disrupt asteroids, particularly carbonaceous asteroids,' researchers said. Nuke Another idea, known simply as 'nuke', involves blowing up a nuclear explosive close to the asteroid. However, this could create smaller but still potentially dangerous fragments of rock that could spin off in all directions, potentially towards Earth. Ion Beam Deflection With Ion Beam Deflection, plumes from a space probe's thrusters would be directed towards the asteroid to gently push on its surface over a wide area. A thruster firing in the opposite direction would be needed to keep the spacecraft at a constant distance from the asteroid. Gravity tractor And yet another concept, gravity tractor, would deflect the asteroid without physically contacting it, but instead by using only its gravitational field to transmit a required impulse. Professor Colin Snodgrass, an astronomer at the University of Edinburgh said: 'There have been a few concepts suggested, such as a 'gravity tractor' to slowly tow an asteroid away instead of pushing it with a kinetic impactor. 'But the kinetic impactor is definitely the simplest technology to use on the sort of timescale that is most likely to be of concern for this size of asteroid, i.e. years to decades warning time.'
